Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major client collaboration for its upcoming Rentschler Biopharma Manufacturing Center (RBMC) facility in Milford, Massachusetts. The RBMC is scheduled to commence operations in the second half of 2024.
The client, a well-established partner of Rentschler Biopharma in Germany, has engaged the RBMC to manufacture its lead product for clinical supply. This groundbreaking protein therapeutic aims to combat a specific type of cancer. Rentschler Biopharma has successfully produced cGMP-quality products for early-phase clinical testing at its manufacturing site in Laupheim, Germany. The project will now transition to the U.S. for additional supply.
The existing Milford site has evolved from a single-product commercial facility to a versatile setup capable of producing multiple products in bioreactors of up to 500 L. The new RBMC, equipped with state-of-the-art technology, will contribute 22,000 square feet of manufacturing cleanroom space and accommodate four new 2,000 L single-use bioreactors. Marking the company's most substantial expansion in its 150-year history, this facility will double Rentschler Biopharma's global cGMP capacity. The primary focus of the facility will be on the commercial production of highly intricate molecules for international clients.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!